LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a target name.
REQUEST A FREE TRIAL
Pipeline
Deals
Financings
Articles
BioCentury
|
Mar 5, 2025
Product Development
A week of endpoint misses and trial halts: BioCentury’s Clinical Report
Bright spot was a slight rise in Protagonist shares on polycythemia vera results
Read More
BioCentury
|
Feb 6, 2024
Deals
Deals roundup: Novo boosts obesity manufacturing with Catalent buy
BioCentury’s weekly roundup of biopharma deals, Jan. 30- Feb. 5
Read More
BioCentury
|
Nov 3, 2022
Management Tracks
Fantaccini becomes head of medical affairs, CSO at Novartis
Plus Maraganore named chair at GNS, and updates from Cardior, Protagonist and Tyra
Read More
BioCentury
|
Apr 15, 2022
Regulation
Protagonist’s Patel says rusfertide on track even as FDA move rattles investors
Agency reassessing breakthrough designation for polycythemia vera after adverse events
Read More
BioCentury
|
Apr 13, 2022
Deals
On heels of catalyst, Sierra picks GSK’s $1.9B takeout over ex-U.S. partnership
After signaling that an ex-U.S. deal was in the works, Sierra chose the M&A route, giving GSK global rights to a late-stage myelofibrosis candidate
Read More
BioCentury
|
Mar 28, 2022
Management Tracks
Asif Ali to join Protagonist as CFO
Plus new CMO at Avenge Bio, new CEO at
Read More
BioCentury
|
Oct 12, 2021
Product Development
Oct. 11 Quick Takes: Supernus diversifies CNS portfolio with Adamas acquisition
Plus: Idorsia’s miss, Evotec, Protagonist, Enzyvant and Chance
Read More
BioCentury
|
Sep 18, 2021
Deals
Sept. 17 Quick Takes: Clinical hold sinks Protagonist shares
Biocon partners with Serum Institute, plus Santé’s $260M fund, IASO Bio’s $108M series C, Everest in $12M renal deal and more
Read More
BioCentury
|
Mar 17, 2020
Finance
With strengthened balance sheet, Keros is latest biotech looking to test IPO market
Keros will look to fund ongoing clinical work via a listing that builds on this month’s series C round
Read More
BioCentury
|
Jan 29, 2020
Company News
Management tracks: Century Therapeutics, Passage, Forbion, Bavarian, Disc, Biocartis, QuantuMDx and more
Read More
Items per page:
10
1 - 10 of 67